Ashley Ross
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Year:
2025
Year:
2025
Patient selection for focal therapy (FT) of prostate cancer requires the assessment of MRI and biopsy results. However, there is currently little guidance for the utility of PSMA PET/CT in FT planning. We describe the case of a man originally considered an ideal candidate for FT based on biopsy and MRI who was found to have a contralateral lesion‐harboring cancer detected only on PSMA PET/CT. Trial Registration: ClinicalTrials.gov identifier: NCT05852041
Year:
2025
Objective This study aimed to evaluate the association of dynamic contrast enhancement (DCE) with clinically significant prostate cancer (csPCa, Gleason Grade Group ≥2) and compare biparametric magnetic resonance imaging (bpMRI) and multiparametric MRI (mpMRI) nomograms. Subjects/patients and methods We identified a retrospective cohort of biopsy naïve patients who underwent pre‐biopsy MRI separated by individual MRI series from 2018 to 2022. csPCa detection rates were calculated for patients with peripheral zone (PZ) lesions scored 3–5 on diffusion weighted imaging (DWI) with available DCE (annotated as − or +). bpMRI Prostate Imaging Reporting and Data System (PIRADS) (3 = 3−, 3+; 4 = 4−, 4+; 5 = 5−, 5+) and mpMRI PIRADS (3 = 3−; 4 = 3+, 4−, 4+; 5 = 5−, 5+) approaches were compared in multivariable logistic regression models. Nomograms for detection of csPCa and ≥GG3 PCa incorporating all biopsy naïve patients who underwent prostate MRI were generated based on available serum biomarkers [PHI, % free prostate‐specific antigen (PSA), or total PSA] and validated with an independent cohort. Results Patients ( n = 1010) with highest PIRADS lesion in PZ were included in initial analysis with 127 (12.6%) classified as PIRADS 3+ (PIRADS 3 on bpMRI but PIRADS 4 on mpMRI). On multivariable analysis, PIRADS 3+ lesions were associated with higher csPCa rates compared to PIRADS 3− (3+ vs. 3−: OR 1.86, p = 0.024), but lower csPCa rates compared to PIRADS DWI 4 lesions (4 vs. 3+: OR 2.39, p < 0.001). csPCa rates were 19% (3−), 31% (3+), 41.5% (4−), 65.9% (4+), 62.5% (5−), and 92.3% (5+). bpMRI nomograms were non‐inferior to mpMRI nomograms in the development ( n = 1410) and independent validation ( n = 353) cohorts. Risk calculators available at: https://rossnm1.shinyapps.io/MynMRIskCalculator/ . Conclusion While DCE positivity by itself was associated with csPCa among patients with highest PIRADS lesions in the PZ, nomogram comparisons suggest that there is no significant difference in performance of bpMRI and mpMRI. bpMRI may be considered as an alternative to mpMRI for prostate cancer evaluation in many situations.
Year:
2024
PURPOSE Few studies have explored the potential for pharmacological interventions to delay disease progression in patients undergoing active surveillance (AS). This preplanned transcriptomic analysis of patient samples from the ENACT trial aims to identify biomarkers in patients on AS who are at increased risk for disease progression or who may derive the greatest benefit from enzalutamide treatment. PATIENTS AND METHODS In the phase II ENACT (ClinicalTrials.gov identifier: NCT02799745 ) trial, patients on AS were randomly assigned 1:1 to 160 mg orally once daily enzalutamide monotherapy or continued AS for 1 year. Transcriptional analyses were conducted on biopsies collected at trial screening, year 1, and year 2. Three gene expression signatures were evaluated in samples collected at screening and in available samples from patients on AS at any time during surveillance (expanded cohort): Decipher genomic classifier, androgen receptor activity (AR-A) score, and Prediction Analysis of Microarray 50 (PAM50) cell subtype signature. RESULTS The Decipher genomic classifier score was prognostic; higher scores were associated with disease progression in the expanded cohort and AS arm of the expanded cohort. Patients with higher Decipher scores had greater positive treatment effect from enzalutamide as measured by time to secondary rise in prostate-specific antigen >25% above baseline. In patients treated with enzalutamide, higher AR-A scores and PAM50 luminal subtypes were associated with a greater likelihood of negative biopsy incidence at year 2. CONCLUSION This analysis suggests that the Decipher genomic classifier may be prognostic for disease progression in AS patients with low- to intermediate-risk prostate cancer. Higher Decipher and AR-A scores, as well as PAM50 luminal subtypes, may also serve as biomarkers for treatment response.
Year:
2024
Background Traditional nomograms can inform the presence of extraprostatic extension (EPE) but not laterality, which remains important for surgical planning, and have not fully incorporated multiparametric MRI data. We evaluated predictors of side-specific EPE on surgical pathology including MRI characteristics and developed side-specific EPE risk calculators. Methods This was a retrospective cohort of patients evaluated with mpMRI prior to radical prostatectomy (RP) in our eleven hospital healthcare system from July 2018-November 2022. The dominant side was defined pre-operatively using a tiered system based on laterality of highest biopsy Gleason Grade Group (GG), highest PIRADS lesion, number of lesions, and cancer volume. Univariable and multivariable logistic regression were performed for overall EPE, dominant side EPE, and non-dominant side EPE. Internal validation with leave one out and calibration curves were completed. Results EPE was identified in 53% (317/601) of patients at RP. Side-specific factors (PIRADS, GG, abutment) were only associated with EPE on their respective side. Final variables in the model associated with EPE on the dominant and non-dominant sides included age, log PSA density (PSAD), side-specific PIRADS 5, side-specific GG3-5, and percentage positivity of systematic cores. AUCs for dominant and non-dominant side EPE were 0.77 (95% CI 0.73-0.80) and 0.79 (95% CI 0.74-0.84), respectively. MRI-identified abutment and prostate health index (PHI) did not improve model discrimination. Risk calculators available online at https://rossnm1.shinyapps.io/PredictionOfEPELaterality/. Conclusions PSA, side-specific PIRADS, side-specific GG, and percentage positivity of systematic cores were associated with side-specific EPE at RP and incorporated into a risk calculator to assist in surgical planning and nerve-sparing decisions at time of RP.
Year:
2024
Background Multiparametric prostate MRI (mpMRI) is being increasingly adopted for work-up of prostate cancer. For patients selected to omit biopsy, we identified factors associated with repeat MRI, eventual prostate biopsy, and subsequent detection of clinically significant prostate cancer (csPCa, Grade Group ≥ 2). Methods We identified biopsy-naïve men presenting with PSA 2–20 ng/mL (March 2018-June 2021) undergoing initial mpMRI with PIRADS 1–3 lesions who were not selected for biopsy with ≥ 6 months follow-up. We examined factors associated with repeat mpMRI, progression to biopsy, and subsequent detection of csPCa with univariable and multivariable logistic regression. Results Of 1494 men, 31% (463/1494) did not pursue biopsy. PSA density (PSAD) ≤ 0.1, prostate health index (PHI) < 55, and PIRADS 1–2 were associated with omission of prostate biopsy. csPCa diagnosis-free survival was 97.6% (326/334) with median follow up of 23.1 months (IQR 15.1–34.6 months). Black race, PSA, PHI, PSA density, and PSA and PHI velocity were significant predictors of undergoing repeat mpMRI (15.6%, 52/334) and subsequent biopsy (8.4%, 28/334). 8 men were subsequently diagnosed with csPCa (N = 7 on prostate biopsy; N = 1 incidentally on holmium enucleation of prostate). All patients diagnosed with csPCa had PIRADS 4–5 on repeat mpMRI. Conclusions The subsequent detection rate of csPCa among patients not initially biopsied after mpMRI was low at 2.4%. Decisions to omit biopsy after reassuring PHI and mpMRI appear safe.
Year:
2024
Year:
2022
Collaborators (3)
Ximing Yang
Professor and Chief of Urological Pathology
Northwestern Medicine
Vikas Mehta
Attending Pathologist
Northwestern Medicine
Yunfei Xie
Fred Hutchinson Cancer Research Center
Make your next move.
Prepare your application
Review drafts before you send them.